Lipella Pharmaceuticals Inc.

NasdaqCM LIPO

Lipella Pharmaceuticals Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Lipella Pharmaceuticals Inc. Net Income Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Lipella Pharmaceuticals Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -4,433.11%.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: LIPO

Lipella Pharmaceuticals Inc.

CEO	Dr. Jonathan Kaufman M.B.A., Ph.D.
IPO Date	Dec. 19, 2022
Location	United States
Headquarters	7800 Susquehanna St.
Employees	5
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Key trends

Past 5 years